AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20398849 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 33
Study 20398849 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy alone
Number of subjects: 33
Study 20398849 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative therapy with concurrent chemoradiotherapy plus fluoropyrimidine-based chemotherapy
Number of subjects: 33
Study 18636998 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized sexual behavior counseling sessions (2 sessions + 3 telephone booster sessions)
Number of subjects: 0
Study 18636998 — intervention group
Group type: COMPARATOR
Intervention: Usual addiction treatment (control group)
Number of subjects: 0
Study 16613263 — intervention group
Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao powder (DXP)
Number of subjects: 63
Study 16613263 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (WMG)
Number of subjects: 63
Study 16613263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DXP and maprotiline
Number of subjects: 63
Study 12756578 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete vitrectomy with silicone oil endotamponade
Number of subjects: 24
Study 12756578 — intervention group
Group type: COMPARATOR
Intervention: Core vitrectomy alone
Number of subjects: 24
Study 10660730 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy based on evidence-based medicine (EBM)
Number of subjects: 0
Study 9138996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic and echocardiographic studies
Number of subjects: 11
Study 9138996 — intervention group
Group type: COMPARATOR
Intervention: Measurements (CC, CA, HA, (CA‐HA) x 100/CA)
Number of subjects: 11
Study 1827010 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 to 2.5 mg twice daily
Number of subjects: 26
Study 1827010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6291439 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen therapy (0.6 mg/d)
Number of subjects: 37
Study 6291439 — intervention group
Group type: COMPARATOR
Intervention: Placebo and low-dose treatment groups
Number of subjects: 37
Study 31144829 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear video with culprit-present lineup
Number of subjects: 472
Study 31144829 — intervention group
Group type: EXPERIMENTAL
Intervention: Degraded video with culprit-present lineup
Number of subjects: 472
Study 31144829 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear video with culprit-removed lineup
Number of subjects: 472
Study 31144829 — intervention group
Group type: EXPERIMENTAL
Intervention: Degraded video with culprit-removed lineup
Number of subjects: 472
Study 31144829 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear video with noise-degraded lineup
Number of subjects: 472
Study 31144829 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise-degraded video with culprit-present lineup
Number of subjects: 472
Study 31144829 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise-degraded video with culprit-removed lineup
Number of subjects: 472
Study 28676065 — intervention group
Group type: COMPARATOR
Intervention: TAVI performed with prior balloon valvuloplasty (control arm)
Number of subjects: 240
Study 28676065 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct implantation of the valve (test arm)
Number of subjects: 240
Study 28676065 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct implantation of the new-generation balloon-expandable SAPIEN 3 valve
Number of subjects: 240
Study 28676065 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of neurological ischemic events with cerebral MRI imaging
Number of subjects: 240
Study 24385387 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 132
Study 24385387 — intervention group
Group type: COMPARATOR
Intervention: Control (no trastuzumab)
Number of subjects: 132
Study 24385387 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and lapatinib after BM
Number of subjects: 132
Study 24385387 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 132
Study 23891167 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated group using navigation software
Number of subjects: 41
Study 23891167 — intervention group
Group type: COMPARATOR
Intervention: Non-navigated group using surgeon judgement
Number of subjects: 41
Study 20340011 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 240
Study 20340011 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20-40 mg/d)
Number of subjects: 240
Study 19056706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin/nutriceutical formulation (folate, vitamin B12, alpha‐tocopherol, S‐adenosyl methionine, N‐acetyl cysteine, and acetyl‐L‐carnitine)
Number of subjects: 12
Study 19056706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19056706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin/nutriceutical formulation
Number of subjects: 12
Study 19255453 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength protocol (3 sets of 5 repetitions at 90% of 1-RM with 3 min rest)
Number of subjects: 15
Study 19255453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy protocol (3 sets of 10 repetitions at 70% with 1 min of rest)
Number of subjects: 15
Study 19255453 — intervention group
Group type: EXPERIMENTAL
Intervention: Power protocol (3 sets of 5 repetitions at 50% with 3 min of rest)
Number of subjects: 15
Study 19255453 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization session (session RPE measured at 5-min intervals for 30 min postexercise)
Number of subjects: 15
Study 15026402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) - 250 mL of 7.5% saline
Number of subjects: 229
Study 15026402 — intervention group
Group type: COMPARATOR
Intervention: Control - 250 mL of Ringer's lactate solution
Number of subjects: 229
Study 11463161 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazol (MMI)
Number of subjects: 56
Study 11463161 — intervention group
Group type: EXPERIMENTAL
Intervention: LAROTABE
Number of subjects: 56
Study 11463161 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI plus LAROTABE
Number of subjects: 56
Study 11463161 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 9664090 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily at bedtime for 12 weeks
Number of subjects: 110
Study 9664090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 7927227 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt
Number of subjects: 43
Study 7927227 — intervention group
Group type: COMPARATOR
Intervention: Emergency medical therapy (intravenous vasopressin and esophageal balloon tamponade) followed by elective portacaval shunt
Number of subjects: 43
Study 7927227 — intervention group
Group type: COMPARATOR
Intervention: Emergency medical therapy
Number of subjects: 43
Study 7927227 — intervention group
Group type: COMPARATOR
Intervention: Emergency medical therapy followed by elective shunt
Number of subjects: 43
Study 3056505 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐mg gemeprost (Cervagem) pessary
Number of subjects: 78
Study 3056505 — intervention group
Group type: COMPARATOR
Intervention: Lamicel tent
Number of subjects: 78
Study 31694122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation training and routine therapy
Number of subjects: 210
Study 31694122 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment only (physical therapy and NSAIDs)
Number of subjects: 210
Study 28339432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar intraarticular pulsed radiofrequency (IAPRF) with 45 V voltage, 2 Hz frequency, 42° C temperature, 10 msec pulse width, and 10 minute duration
Number of subjects: 100
Study 28339432 — intervention group
Group type: COMPARATOR
Intervention: Unipolar intraarticular pulsed radiofrequency (IAPRF) with 45 V voltage, 2 Hz frequency, 42° C temperature, 10 msec pulse width, and 10 minute duration
Number of subjects: 100
Study 28339432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar intraarticular pulsed radiofrequency (IAPRF)
Number of subjects: 100
Study 28339432 — intervention group
Group type: COMPARATOR
Intervention: Unipolar intraarticular pulsed radiofrequency (IAPRF)
Number of subjects: 100
Study 25365130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotizability (high vs low)
Number of subjects: 0
Study 25365130 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative suggestion about performance
Number of subjects: 0
Study 25365130 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive suggestion about performance
Number of subjects: 0
Study 25365130 — intervention group
Group type: COMPARATOR
Intervention: Prehypnotic suggestion
Number of subjects: 0
Study 25365130 — intervention group
Group type: COMPARATOR
Intervention: Feedback suggestion during encoding or retrieval
Number of subjects: 0
Study 22913474 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ICD
Number of subjects: 1271
Study 22913474 — intervention group
Group type: COMPARATOR
Intervention: ICD
Number of subjects: 1271
Study 22913474 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ICD (LBBB subgroup)
Number of subjects: 1271
Study 22913474 — intervention group
Group type: COMPARATOR
Intervention: ICD (non-LBBB group)
Number of subjects: 1271
Study 20846961 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 75
Study 20846961 — intervention group
Group type: COMPARATOR
Intervention: Centre-based cardiac rehabilitation
Number of subjects: 75
Study 18165563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine plus dexamethasone (group M + D)
Number of subjects: 80
Study 16879679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 301
Study 16879679 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic urethral support sling (SPARC)
Number of subjects: 301
Study 12911659 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 14
Study 12911659 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 14
Study 10881615 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinate spatial descriptions
Number of subjects: 0
Study 10881615 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate spatial descriptions
Number of subjects: 0
Study 10881615 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal descriptions
Number of subjects: 0
Study 10881615 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition test with manipulated similarity between foils and original descriptions
Number of subjects: 0
Study 9108457 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF gene‐transduced vaccines
Number of subjects: 16
Study 9108457 — intervention group
Group type: COMPARATOR
Intervention: Nontransduced vaccines
Number of subjects: 16
Study 9108457 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF gene‐transduced vaccine
Number of subjects: 16
Study 8254871 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA-P group (n = 10): epidural pethidine plus 0.25% bupivacaine
Number of subjects: 20
Study 8254871 — intervention group
Group type: COMPARATOR
Intervention: PCEA-B group (n = 10): epidural buprenorphine plus 0.25% bupivacaine
Number of subjects: 20
Study 8254871 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA-P and PCEA-B
Number of subjects: 20
Study 8254871 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA-P
Number of subjects: 20
Study 2860136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 20 to 30 mg/day
Number of subjects: 0
Study 2860136 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam, 2 mg/day
Number of subjects: 0
Study 2860136 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 30188941 — intervention group
Group type: EXPERIMENTAL
Intervention: Trustworthy face
Number of subjects: 0
Study 30188941 — intervention group
Group type: COMPARATOR
Intervention: Untrustworthy face
Number of subjects: 0
Study 30188941 — intervention group
Group type: COMPARATOR
Intervention: Upside down faces
Number of subjects: 0
Study 27473327 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-entered self-monitoring method using an activity tracker
Number of subjects: 64
Study 27473327 — intervention group
Group type: COMPARATOR
Intervention: User-entered self-monitoring method (manual recording)
Number of subjects: 64
Study 23992231 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% concentrated sodium chloride (CSC)
Number of subjects: 72
Study 23992231 — intervention group
Group type: COMPARATOR
Intervention: 3125 U/mL heparin saline (HS)
Number of subjects: 72
Study 22066790 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 485
Study 22066790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 485
Study 22066790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 22066790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 485
Study 22066790 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 485
Study 20808854 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) and L-carnitine for 6 months
Number of subjects: 61
Study 20808854 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) and L-carnitine for 12 months (post-hoc analysis)
Number of subjects: 61
Study 20808854 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 61
Study 20808854 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (VPA and L-carnitine)
Number of subjects: 61
Study 20808854 — intervention group
Group type: EXPERIMENTAL
Intervention: Age factor in treatment
Number of subjects: 61
Study 17656831 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback tracking training (VBTT) for 39 minutes/day, 5 days/week, for 4 weeks
Number of subjects: 10
Study 17656831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 10
Study 15601808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine given 1 hour after alfentanil followed by a meal containing orange or apple juice
Number of subjects: 0
Study 15601808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine given 1 hour after alfentanil followed by a meal not containing citrus or apple products
Number of subjects: 0
Study 15601808 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 0
Study 15601808 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine alone
Number of subjects: 0
Study 12099628 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cycle IVF
Number of subjects: 1800
Study 12099628 — intervention group
Group type: COMPARATOR
Intervention: IVF with ovarian stimulation
Number of subjects: 1800
Study 10449882 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy children
Number of subjects: 400
Study 10449882 — intervention group
Group type: COMPARATOR
Intervention: Children with congenital heart disease
Number of subjects: 400
Study 10449882 — intervention group
Group type: EXPERIMENTAL
Intervention: Variables dependent on vagal tone (rMSSD, pNN50, HF)
Number of subjects: 400
Study 10449882 — intervention group
Group type: EXPERIMENTAL
Intervention: SDNN and SDANNi
Number of subjects: 400
Study 7600115 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (2 IU.m‐2.d‐1)
Number of subjects: 11
Study 7600115 — intervention group
Group type: COMPARATOR
Intervention: Insulin-like growth factor-I (80 micrograms.kg‐1.d‐1)
Number of subjects: 11
Study 2145790 — intervention group
Group type: COMPARATOR
Intervention: Inhaled albuterol (A) alone
Number of subjects: 12
Study 2145790 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (A) plus ipratropium bromide (IB)
Number of subjects: 12
Study 1130891 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red cells
Number of subjects: 294
Study 1130891 — intervention group
Group type: COMPARATOR
Intervention: Whole blood
Number of subjects: 294
Study 30685489 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy
Number of subjects: 105
Study 30685489 — intervention group
Group type: COMPARATOR
Intervention: Open pancreatoduodenectomy
Number of subjects: 105
Study 28885348 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 134
Study 28885348 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 134
Study 25925992 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 108
Study 25925992 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 108
Study 25925992 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg plus UFH
Number of subjects: 108
Study 25925992 — intervention group
Group type: COMPARATOR
Intervention: Standard peri-procedural UFH
Number of subjects: 108
Study 24120550 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-v (250 μg or 500 μg, either alone or adjuvanted with ISA-51)
Number of subjects: 59
Study 24120550 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-v (high adjuvanted dose)
Number of subjects: 59
Study 24120550 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-v (in responding subjects)
Number of subjects: 59
Study 24120550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 22143997 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/day
Number of subjects: 1569
Study 22143997 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 1569
Study 22143997 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 1569
Study 22143997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1569
Study 22143997 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/day and 150 mg/day
Number of subjects: 1569
Study 19808134 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once daily for 3 months
Number of subjects: 31
Study 19808134 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 3 months
Number of subjects: 31
Study 16686768 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Number of subjects: 122
Study 16686768 — intervention group
Group type: COMPARATOR
Intervention: Open donor nephrectomy
Number of subjects: 122
Study 15367476 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice about safe sex and complementary resources from family physicians (FPs)
Number of subjects: 312
Study 15367476 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CONTROL group)
Number of subjects: 312
Study 11116754 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg) co-administered with tolbutamide (500 mg)
Number of subjects: 9
Study 11116754 — intervention group
Group type: COMPARATOR
Intervention: Tolbutamide (500 mg) alone
Number of subjects: 9
Study 9200247 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery and verbal labeling
Number of subjects: 0
Study 9200247 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 0
Study 9200247 — intervention group
Group type: COMPARATOR
Intervention: No rehearsal strategy (control condition)
Number of subjects: 0
Study 9200247 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided movement
Number of subjects: 0
Study 8371129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg iv loading dose followed by 1 mg/hour continuous infusion for the treatment period)
Number of subjects: 40
Study 8371129 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (60 mg/m2/day by continuous infusion for the same period, maximum 8 days)
Number of subjects: 40
Study 3524334 — intervention group
Group type: EXPERIMENTAL
Intervention: R3: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months
Number of subjects: 694
Study 3524334 — intervention group
Group type: EXPERIMENTAL
Intervention: R5: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months followed by streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months
Number of subjects: 694
Study 3524334 — intervention group
Group type: EXPERIMENTAL
Intervention: Z5: the same as regimen R5 but without rifampin
Number of subjects: 694
Study 3524334 — intervention group
Group type: COMPARATOR
Intervention: R3
Number of subjects: 694
Study 3524334 — intervention group
Group type: COMPARATOR
Intervention: R5
Number of subjects: 694
Study 3524334 — intervention group
Group type: COMPARATOR
Intervention: Z5
Number of subjects: 694
Study 3524334 — intervention group
Group type: COMPARATOR
Intervention: R3 and R5 combined
Number of subjects: 694
Study 30453599 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient physiotherapy (InPhysio)
Number of subjects: 104
Study 30453599 — intervention group
Group type: COMPARATOR
Intervention: Home-based physiotherapy (HomePhysio)
Number of subjects: 104
Study 27912741 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Kiosk and nutritional education (KSEAN)
Number of subjects: 1655
Study 27912741 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized physical activity (AFSO)
Number of subjects: 1655
Study 27912741 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Kiosk and nutritional education (KSEAN) + optimized physical activity (AFSO)
Number of subjects: 1655
Study 27912741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1655
Study 24770985 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (4 group and 4 individual sessions) integrating risk reduction counseling with counseling to foster self-acceptance
Number of subjects: 96
Study 24770985 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care (ESOC)
Number of subjects: 96
Study 24770985 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 96
Study 22723583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia (achieved median A1C of 6.4%)
Number of subjects: 7287
Study 22723583 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemia (achieved median A1C of 7.5%)
Number of subjects: 7287